AllergyStop®: Patent Pending
Allergy Medical is devoted to creating a safe, portable, and affordable epinephrine device. AllergyStop® is the first device in a potential line of epinephrine devices. It is completely functional and used by it’s founder Dr. Douglas McMahon. IP protection is in place by Merchant and Gould Law firm. CMO’s are currently placing bids and an FDA path is in place with FDA consultants working daily with Allergy Medical.
Capital funding is necessary to begin our road to production. Before initial device testing can begin, capital must be acquired to cover material costs, device manufacturing and testing. Medical devices require thorough analysis and clinical testing to ensure proper dispensing and device function under FDA regulations. The estimated cost to take the device to production is $3 million. We are currently seeking $1 million in our round A investments.
Allergy Medical is classified under the Minnesota Angel Tax Credit. Minnesota's Angel Tax Credit provides a 25-percent credit to investors or investment funds that put money into startup companies focused on high technology, new proprietary technology, or a new proprietary product, process or service in specified fields. The maximum credit is $125,000 per person, per year ($250,000 if filing jointly). The credit is refundable. Residents of other states and foreign countries are eligible. See the following link for more information. http://mn.gov/deed/business/financing-business/tax-credits/angel-tax-credit/for-investors.jsp
If you would potentially like to invest please contact us via the website or you can e-mail Dr. McMahon directly at email@example.com
Why You Should Care
Every 3 minutes, a food allergy reaction sends someone to the emergency department (More than 200,000 visits per year). Our goal is to stop these events and alleviate the fear of anaphylaxis from millions of people. Investing will propel AllergyStop® toward production and into the hands of those we care about most.
Whether you live with severe allergies or not, investing to our foundation will bring AllergyStop® one step closer to rescuing that friend or family member who neglected their epinephrine device at home.
A portion of all sales will go toward food allergy research upon mass market distribution.
AllergyStop is an investigational drug and has not yet been approved by the US Food Drug Administration for distribution in the US.